公开(公告)号：EP3082856A1

公开(公告)日：2016-10-26

申请号：EP14830912.3

申请日：2014-12-15

申请人： Zoetis Services LLC

发明人： EDWARDS, Nigel ,  HUANG, Jinan ,  WAREING, Mark

IPC分类号： A61K39/155

CPC分类号： A61K39/155 ,  A61K39/12 ,  A61K2039/525 ,  A61K2039/545 ,  A61K2039/552 ,  A61K2039/55577 ,  A61K2039/575 ,  C12N7/00 ,  C12N2760/18022 ,  C12N2760/18034 ,  C12N2760/18071 ,  C12N2760/18222 ,  C12N2760/18234 ,  C12N2760/18271

摘要： This invention relates to Hendra and Nipah immunogenic compositions and methods of use. The invention also relates to methods of distinguishing subjects vaccinated with the immunogenic compositions of the invention from those infected with Hendra and/or Nipah virus.

公开(公告)号：EP2833901A4

公开(公告)日：2015-12-16

申请号：EP13772650

申请日：2013-04-04

申请人： SCRIPPS RESEARCH INST

发明人： SCHIEF WILLIAM R

IPC分类号： A61K38/08

CPC分类号： A61K39/385 ,  A61K38/00 ,  A61K2039/6068 ,  A61K2039/64 ,  C07K14/00 ,  C07K14/005 ,  C07K2319/35 ,  C12N7/00 ,  C12N2760/18022 ,  C12N2760/18023 ,  C12N2760/18034 ,  G01N33/6854

公开(公告)号：EP1714974A3

公开(公告)日：2007-03-21

申请号：EP05077520.4

申请日：1995-12-20

申请人： Duke University ,  TRIMERIS INC.

发明人： Bolognesi, Dani P. ,  Matthews, Thomas J. ,  Wild, Cart T. ,  Barney, Shawn O'Lin ,  Lambert, Dennis M. ,  Pettewey, Stephen R., Jr. ,  Langlois, Alphonse J.

IPC分类号： C07K7/04 ,  C07K14/025 ,  C07K14/16 ,  C12N9/94 ,  C12N9/96 ,  C12N9/98 ,  C12N9/99

CPC分类号： C07K14/005 ,  A61K38/00 ,  A61K39/00 ,  A61K2039/525 ,  A61K2039/555 ,  A61K2039/60 ,  A61K2039/6031 ,  C07K5/0806 ,  C07K5/0808 ,  C07K5/0812 ,  C07K5/0817 ,  C07K5/0819 ,  C07K5/1008 ,  C07K5/101 ,  C07K5/1013 ,  C07K5/1016 ,  C07K5/1021 ,  C07K5/1024 ,  C07K14/21 ,  C07K14/22 ,  C07K14/245 ,  C07K14/285 ,  C07K14/31 ,  C07K2319/00 ,  C12N7/00 ,  C12N2710/16222 ,  C12N2730/10122 ,  C12N2740/13022 ,  C12N2740/14022 ,  C12N2740/15022 ,  C12N2740/16122 ,  C12N2740/16222 ,  C12N2740/17022 ,  C12N2760/16122 ,  C12N2760/18022 ,  C12N2760/18122 ,  C12N2760/18422 ,  C12N2760/18522 ,  C12N2760/18622 ,  C12N2760/18722 ,  G01N33/5008 ,  G01N33/502 ,  G01N33/505 ,  G01N33/5091 ,  Y10S530/826

摘要： The present invention relates to peptides which exhibit potent anti-retroviral activity. The peptides of the invention comprise DP178 (SEQ ID:1) peptide corresponding to amino acids 638 to 673 of the HIV-1LAI gp41 protein, and fragments, analogs and homologs of DP178. The invention further relates to the uses of such peptides as inhibitory of human and non-human retroviral, especially HIV, transmission to uninfected cells.

公开(公告)号：EP0595970A4

公开(公告)日：1995-05-31

申请号：EP92916278

申请日：1992-07-17

申请人： COMMW SCIENT IND RES ORG

发明人： WALKER PETER JOHN ,  PREHAUD CHRISTOPHE JEAN

IPC分类号： A61K39/00 ,  A61K39/155 ,  A61K39/205 ,  A61P31/12 ,  C07K14/115 ,  C07K14/145 ,  C12N7/00 ,  C12N7/01 ,  C12N7/04 ,  C12N15/09 ,  C12R1/92 ,  A61K39/175 ,  C12N15/45 ,  C12N15/47 ,  C12N15/86

CPC分类号： C07K14/005 ,  A61K39/00 ,  A61K39/12 ,  A61K39/205 ,  A61K2039/5258 ,  C12N7/00 ,  C12N2710/14143 ,  C12N2760/18022 ,  C12N2760/20122 ,  C12N2760/20123 ,  C12N2760/20134

公开(公告)号：EP2316924B1

公开(公告)日：2017-10-11

申请号：EP10181856.5

申请日：1999-06-11

申请人： Icahn School of Medicine at Mount Sinai

发明人： Palese, Peter ,  Garcia-Sastre, Adolfo ,  Muster, Thomas

IPC分类号： C12N7/00 ,  A61P31/16 ,  A61K39/145

CPC分类号： A61K39/145 ,  A61K39/0011 ,  A61K39/12 ,  A61K39/155 ,  A61K39/17 ,  A61K39/205 ,  A61K2039/525 ,  A61K2039/5254 ,  A61K2039/5256 ,  A61K2039/543 ,  A61K2039/552 ,  A61K2039/572 ,  A61K2039/585 ,  C07K14/005 ,  C12N7/00 ,  C12N15/86 ,  C12N2760/16121 ,  C12N2760/16122 ,  C12N2760/16132 ,  C12N2760/16134 ,  C12N2760/16143 ,  C12N2760/16151 ,  C12N2760/16161 ,  C12N2760/16162 ,  C12N2760/16171 ,  C12N2760/16221 ,  C12N2760/16222 ,  C12N2760/16232 ,  C12N2760/16234 ,  C12N2760/16243 ,  C12N2760/16251 ,  C12N2760/16262 ,  C12N2760/16271 ,  C12N2760/18022 ,  C12N2760/18034 ,  C12N2760/18122 ,  C12N2760/18134 ,  C12N2760/18522 ,  C12N2760/18534 ,  C12N2760/20222 ,  C12N2760/20234 ,  Y02A50/466

摘要： The present invention relates, in general, to attenuated negative-strand RNA viruses having an impaired ability to antagonize the cellular interferon (IFN) response, and the use of such attenuated viruses in vaccine and pharmaceutical formulations. The invention also relates to the development and use of IFN-deficient systems for selection of such attenuated viruses. In particular, the invention relates to attenuated influenza viruses having modifications to the NS1 gene that diminish or eliminate the ability of the NS1 gene product to antagonize the cellular IFN response. The mutant viruses replicate in vivo but demonstrate reduced pathogenicity, and therefore are well suited for live virus vaccines, and pharmaceutical formulations.

公开(公告)号：EP2356257A1

公开(公告)日：2011-08-17

申请号：EP09784341.1

申请日：2009-11-17

申请人： Centre National de la Recherche Scientifique ,  Universite Claude Bernard de Lyon 1 ,  Les Hospices Civils de Lyon

发明人： ROSA CALATRAVA, Manuel, Melchior, Jean-Pierre ,  TERRIER, Olivier ,  DURUPT, François, Edouard, Julien

IPC分类号： C12Q1/68 ,  C07K14/115

CPC分类号： C07K14/005 ,  C12N2760/18022 ,  C12N2760/18722

摘要： The invention relates to two mutant proteins of the fusion protein (F protein) of the
Parainfluenza virus (PIV) currently recorded as type-5 PFV (PIV-5 or PIV5) and type-2 PIV (PIV-2 or PIV2). The present invention relates to products derived therefrom such as: nucleic acids, vectors, cells; fusion inhibitors of the antibody, aptamers, interfering RNA; myelomae, hybridomae, progenitor and stem cells. The present invention also relates to said mutant proteins and products derived therefrom used in medical applications and biotechnologies.

公开(公告)号：EP2316924A2

公开(公告)日：2011-05-04

申请号：EP10181856.5

申请日：1999-06-11

申请人： Mount Sinai School of Medicine of New York University

发明人： Palese, Peter ,  Garcia-Sastre, Adolfo ,  Muster, Thomas

IPC分类号： C12N7/00 ,  A61K39/12

CPC分类号： A61K39/145 ,  A61K39/0011 ,  A61K39/12 ,  A61K39/155 ,  A61K39/17 ,  A61K39/205 ,  A61K2039/525 ,  A61K2039/5254 ,  A61K2039/5256 ,  A61K2039/543 ,  A61K2039/552 ,  A61K2039/572 ,  A61K2039/585 ,  C07K14/005 ,  C12N7/00 ,  C12N15/86 ,  C12N2760/16121 ,  C12N2760/16122 ,  C12N2760/16132 ,  C12N2760/16134 ,  C12N2760/16143 ,  C12N2760/16151 ,  C12N2760/16161 ,  C12N2760/16162 ,  C12N2760/16171 ,  C12N2760/16221 ,  C12N2760/16222 ,  C12N2760/16232 ,  C12N2760/16234 ,  C12N2760/16243 ,  C12N2760/16251 ,  C12N2760/16262 ,  C12N2760/16271 ,  C12N2760/18022 ,  C12N2760/18034 ,  C12N2760/18122 ,  C12N2760/18134 ,  C12N2760/18522 ,  C12N2760/18534 ,  C12N2760/20222 ,  C12N2760/20234 ,  Y02A50/466

摘要： The present invention relates, in general, to attenuated negative-strand RNA viruses having an impaired ability to antagonize the cellular interferon (IFN) response, and the use of such attenuated viruses in vaccine and pharmaceutical formulations. The invention also relates to the development and use of IFN-deficient systems for selection of such attenuated viruses. In particular, the invention relates to attenuated influenza viruses having modifications to the NS1 gene that diminish or eliminate the ability of the NS1 gene product to antagonize the cellular IFN response. The mutant viruses replicate in vivo but demonstrate reduced pathogenicity, and therefore are well suited for live virus vaccines, and pharmaceutical formulations.

摘要翻译： 本发明涉及，在一般情况下，衰减具有拮抗细胞干扰素（IFN）反应能力受损，并且在疫苗和药物配方和灰的使用搜索减毒病毒负海滩RNA病毒。 因此，本发明涉及开发和使用IFN缺陷系统的的搜索减毒病毒的选择。 特别地，本发明涉及减毒具有修改对NS1基因并减少或消除的NS1基因产物的拮抗细胞IFN应答的能力的流感病毒。 突变病毒复制体内但展示出降低的致病性，并且因此非常适合用于活病毒疫苗和药物配方和灰。

公开(公告)号：EP1545625A4

公开(公告)日：2008-05-07

申请号：EP03736977

申请日：2003-06-06

申请人： KENTUCKY BIOPROC LLC

发明人： MCCORMICK ALISON A ,  SMITH MARK L ,  PALMER KENNETH E ,  LINDBO JOHN A ,  NGUYEN LONG V ,  POGUE GREGORY P

IPC分类号： A61K20060101 ,  A61K39/12 ,  A61K39/385 ,  A61K48/00 ,  C07K14/025 ,  C07K14/08 ,  C07K14/11 ,  C07K14/115 ,  C07K14/12 ,  C07K14/47 ,  C07K19/00 ,  C12N7/00 ,  C12N7/01 ,  C12N7/04 ,  C12N15/86

CPC分类号： C07K14/005 ,  A61K39/0011 ,  A61K39/12 ,  A61K39/385 ,  A61K2039/5258 ,  A61K2039/55516 ,  A61K2039/6075 ,  A61K2039/627 ,  A61K2039/64 ,  C07K14/4748 ,  C07K2319/00 ,  C12N7/00 ,  C12N2710/20022 ,  C12N2710/20034 ,  C12N2760/16122 ,  C12N2760/18022 ,  C12N2770/00022 ,  C12N2770/00023

公开(公告)号：EP1086207B1

公开(公告)日：2007-01-17

申请号：EP99927443.4

申请日：1999-06-11

申请人： MOUNT SINAI SCHOOL OF MEDICINE OF THE CITY UNIVERSITY OF NEW YORK

发明人： PALESE, Peter ,  GARCIA-SASTRE, Adolfo ,  O'NEIL, Robert

IPC分类号： C12N7/00 ,  A61K39/12

CPC分类号： A61K39/145 ,  A61K39/0011 ,  A61K39/12 ,  A61K39/155 ,  A61K39/17 ,  A61K39/205 ,  A61K2039/525 ,  A61K2039/5254 ,  A61K2039/5256 ,  A61K2039/543 ,  A61K2039/552 ,  A61K2039/572 ,  A61K2039/585 ,  C07K14/005 ,  C12N7/00 ,  C12N15/86 ,  C12N2760/16121 ,  C12N2760/16122 ,  C12N2760/16132 ,  C12N2760/16134 ,  C12N2760/16143 ,  C12N2760/16151 ,  C12N2760/16161 ,  C12N2760/16162 ,  C12N2760/16171 ,  C12N2760/16221 ,  C12N2760/16222 ,  C12N2760/16232 ,  C12N2760/16234 ,  C12N2760/16243 ,  C12N2760/16251 ,  C12N2760/16262 ,  C12N2760/16271 ,  C12N2760/18022 ,  C12N2760/18034 ,  C12N2760/18122 ,  C12N2760/18134 ,  C12N2760/18522 ,  C12N2760/18534 ,  C12N2760/20222 ,  C12N2760/20234 ,  Y02A50/466

摘要： The present invention relates, in general, to attenuated negative-strand RNA viruses having an impaired ability to antagonize the cellular interferon (IFN) response, and the use of such attenuated viruses in vaccine and pharmaceutical formulations. The invention also relates to the development and use of IFN-deficient systems for selection of such attenuated viruses. In particular, the invention relates to attenuated influenza viruses having modifications to the NS1 gene that diminish or eliminate the ability of the NS1 gene product to antagonize the cellular IFN response. The mutant viruses replicate in vivo but demonstrate reduced pathogenicity, and therefore are well suited for live virus vaccines, and pharmaceutical formulations.

公开(公告)号：EP1714974A2

公开(公告)日：2006-10-25

申请号：EP05077520.4

申请日：1995-12-20

申请人： Duke University ,  TRIMERIS INC.

发明人： Bolognesi, Dani P. ,  Matthews, Thomas J. ,  Wild, Cart T. ,  Barney, Shawn O'Lin ,  Lambert, Dennis M. ,  Pettewey, Stephen R., Jr. ,  Langlois, Alphonse J.

IPC分类号： C07K7/04 ,  C07K14/025 ,  C07K14/16 ,  C12N9/94 ,  C12N9/96 ,  C12N9/98 ,  C12N9/99

CPC分类号： C07K14/005 ,  A61K38/00 ,  A61K39/00 ,  A61K2039/525 ,  A61K2039/555 ,  A61K2039/60 ,  A61K2039/6031 ,  C07K5/0806 ,  C07K5/0808 ,  C07K5/0812 ,  C07K5/0817 ,  C07K5/0819 ,  C07K5/1008 ,  C07K5/101 ,  C07K5/1013 ,  C07K5/1016 ,  C07K5/1021 ,  C07K5/1024 ,  C07K14/21 ,  C07K14/22 ,  C07K14/245 ,  C07K14/285 ,  C07K14/31 ,  C07K2319/00 ,  C12N7/00 ,  C12N2710/16222 ,  C12N2730/10122 ,  C12N2740/13022 ,  C12N2740/14022 ,  C12N2740/15022 ,  C12N2740/16122 ,  C12N2740/16222 ,  C12N2740/17022 ,  C12N2760/16122 ,  C12N2760/18022 ,  C12N2760/18122 ,  C12N2760/18422 ,  C12N2760/18522 ,  C12N2760/18622 ,  C12N2760/18722 ,  G01N33/5008 ,  G01N33/502 ,  G01N33/505 ,  G01N33/5091 ,  Y10S530/826

摘要： The present invention relates to peptides which exhibit potent anti-retroviral activity. The peptides of the invention comprise DP178 (SEQ ID:1) peptide corresponding to amino acids 638 to 673 of the HIV-1LAI gp41 protein, and fragments, analogs and homologs of DP178. The invention further relates to the uses of such peptides as inhibitory of human and non-human retroviral, especially HIV, transmission to uninfected cells.

摘要翻译： 本发明涉及一种显示出有效的抗逆转录病毒活性的肽。 本发明包括DP178的肽（SEQ ID：1）的肽对应于氨基酸638到HIV-1 gp41的LAI蛋白质673，和片段，类似物和DP178的同源物。 本发明还涉及到寻找肽作为人类和非人类逆转录病毒的抑制，爱特别是HIV，传输对未感染细胞的用途。